AbbVie released the results of H2H Phase 3 data showing the superiority of Skyrizi over Cosentyx
87% of patients on Skyrizi achieved PASI 90 compared 57% in patients on Cosentyx at week 52
AbbVie announced the results of Skyrizi (risankizumab), showing the superiority over Cosentyx (secukinumab) at week 52. The company has announced that Skyrizi (risankizumab) achieved both the primary and secondary endpoints. Skin clearance was higher in patients on Skyrizi compared to patients on Cosentyx. 87% of patients on
Skyrizi achieved PASI 90 compared to 57% in patients on Cosentyx at week 52. At week 16, the other primary endpoint was non-inferiority to Cosentyx; 74% of Skyrizi achieved PASI 90 compared to 66% in patients on Cosentyx.
"In this study, SKYRIZI showed superior efficacy compared to Cosentyx in helping patients achieve and maintain high levels of skin clearance at week 52," said Michael Severino, vice chairman and president, AbbVie.
In the head-to-head Pase 3 study, patients were randomized 1:1 to Skyrizi and Consentyx. The dosing of Skyrizi was two 75 mg subcutaneous injections at baseline, four weeks later and every 12 weeks after that. Cosentyx dosage was two 150 mg subcutaneous injections, at baseline, weeks 1, 2, 3, and 4, and then every four weeks after that.
AbbVie developed Skyrizi in collaboration with Boehringer Ingelheim.